Introduction: Echinacea purpurea is a flowering plant commonly used as an herbal medicine despite insufficient scientific bases to validate its usage. The present study aimed to examine in vitro and in vivo hepatoprotective effects of aqueous and alcoholic extracts of E. purpurea flowers. Methods: In vitro protection against hepato-cytotoxicity was carried out on human HepG-2 cells using colorimetric tetrazolium (MTT) assay, while the in vivo hepatoprotective activity was studied against carbon-tetrachloride (CCl4) induced acute hepatotoxicity in rats. Results: The results revealed that the extracts of E. purpurea induced discernable in vitro protection on HepG-2 cells and in vivo against CCl4 induced hepatotoxicity. Both extracts were significantly able to restore the serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, total protein, and albumin to normal levels compared to the CCl4 intoxicated group. In addition, the extracts markedly mitigated the oxidative stress by decreasing Malondialdehyde (MDA) and increasing superoxide dismutase (SOD) and glutathione (GSH) markers compared to the CCl4 intoxicated group. It was also associated with the down-regulation of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels in liver tissues. Histopathological examination revealed a decrease in hepatocytes’ degenerative changes and noticeable improvement of the liver damage by extracts of E. purpurea. Conclusion: These findings have proven that aqueous and alcoholic extracts of E. purpurea flowers have a significant hepatoprotective effect, probably owing to antioxidant, anti-inflammatory activities, and regulating apoptotic-related genes. This confirms the ethnomedicinal uses of E. purpurea in patients suffering from liver diseases.
1 October 2026 in Journal of Pharmacy and Pharmacology
Objectives: This research was designed to assess the impact and underlying pathways of the root aqueous extract of Moghat root (MRE) on metabolic syndrome (MS). Methods: The extract’s constituents were identified through HPLC analysis, followed by evaluation of its impact on lipid and glucose metabolism using in vitro and in vivo assays. Key findings: In a high-fat high-carbohydrate diet, streptozotocin animal model-induced MS, MRE increased fat accumulation and diminished the genes expression included in lipogenesis. Moreover, the extract enhanced obesity, the resistance of insulin, the amounts of lipid, oxidative stress, and hepatic function in MS rats after a 4 weeks intervention orally with the extract at 100 and 200 mg/kg related to metformin at 200 mg/kg after verification of diabetes. MRE decreased the expression of hepatic INSR, Srebf1, mTOR, PI3K, AKT, NF-κβ, and IL-6 through the PI3K/AKT/mTOR signaling pathway to inhibit inflammation and lipid accumulation and achieve its hypolipidemic effect. Moreover, MRE decreased the expression of MYD88 and p38 MAPK which was confirmed in liver tissue by using IHC analysis. Conclusions: Our data proposed that MRE could improve MS by improving lipid metabolism via numerous pathways and can be progressed into dietary supplements for the correction of MS.